DCM
SCNI

DAFNA Capital Management’s Scinai Immunotherapeutics SCNI Stock Holding History

DAFNA Capital Management’s Portfolio SCNI Stock Details SCNI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-34
Closed -$18K – 81
2018
Q1 		$18K Buy
+34
New +$21.2K 0.01% 75

Other funds holding SCNI

II
Ibex Investors Denver, Colorado $152M AUM 19.17% 1-Year Est. Return
BHB
Bank Hapoalim BM Tel Aviv, Israel $652M AUM 19.01% 1-Year Est. Return
VIA
Vantage Investment Advisors State College, Pennsylvania $477M AUM 17.38% 1-Year Est. Return
HighTower Advisors
HighTower Advisors Chicago, Illinois $94.2B AUM 21.24% 1-Year Est. Return
PVH
Psagot Value Holdings Tel Aviv, Israel $11M AUM 32.09% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
LTFS
Ladenburg Thalmann Financial Services Miami, Florida $15.9B AUM 25.16% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

DAFNA Capital Management's SCNI Position: Q2 2018 in Review

DAFNA Capital Management sold out of Scinai Immunotherapeutics (SCNI) in Q2 2018, closing a stake of 34 shares — an estimated $18K sold.

DAFNA Capital Management first reported a position in SCNI in Q1 2018 and held it in 1 quarter. The position peaked at $18K in Q1 2018. 12 funds tracked by Wall St. Rank hold SCNI as of Q2 2018.

  • DAFNA Capital Management reported no remaining Scinai Immunotherapeutics position as of Q2 2018 after selling out during the quarter.
  • DAFNA Capital Management sold 34 Scinai Immunotherapeutics shares in Q2 2018, an estimated $18K.
  • DAFNA Capital Management first reported a position in Scinai Immunotherapeutics in Q1 2018 and held it in 1 quarter.
  • DAFNA Capital Management's Scinai Immunotherapeutics position peaked at $18K in Q1 2018.
  • 12 funds tracked by Wall St. Rank held Scinai Immunotherapeutics as of Q2 2018.

Based on DAFNA Capital Management's 13F filing for Q2 2018, filed 13 Aug 2018.